Inovio Pharmaceuticals (INO) Upgraded at BidaskClub

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Wednesday.

Several other research firms also recently commented on INO. HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, January 3rd. ValuEngine downgraded Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. Royal Bank of Canada initiated coverage on Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 target price on the stock. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Maxim Group set a $12.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $19.16.

Inovio Pharmaceuticals (NASDAQ:INO) traded down $0.08 during trading on Wednesday, reaching $5.05. The company had a trading volume of 1,544,549 shares, compared to its average volume of 1,650,000. Inovio Pharmaceuticals has a fifty-two week low of $4.09 and a fifty-two week high of $9.86. The stock has a market capitalization of $456.00, a P/E ratio of -4.28 and a beta of 2.74.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The firm had revenue of $2.60 million during the quarter, compared to analysts’ expectations of $10.27 million. During the same quarter in the previous year, the company posted ($0.28) EPS. Inovio Pharmaceuticals’s revenue for the quarter was down 79.2% on a year-over-year basis. research analysts anticipate that Inovio Pharmaceuticals will post -1.12 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. BlueCrest Capital Management Ltd bought a new position in shares of Inovio Pharmaceuticals in the second quarter worth $107,000. Virginia Retirement Systems ET AL bought a new position in shares of Inovio Pharmaceuticals in the third quarter worth $101,000. Neuberger Berman Group LLC bought a new position in shares of Inovio Pharmaceuticals in the third quarter worth $115,000. Engineers Gate Manager LP bought a new position in shares of Inovio Pharmaceuticals in the third quarter worth $117,000. Finally, Emerald Advisers Inc. PA increased its holdings in shares of Inovio Pharmaceuticals by 84.0% in the third quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 9,280 shares during the period. 32.11% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/28/inovio-pharmaceuticals-ino-upgraded-at-bidaskclub.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply